ArticleTherapeutic advances in hematology2026

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents.

Amer M Zeidan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.